HuL001

DRUG2 trials

Sponsors

HuniLife Biotechnology, Inc.

Conditions

Idiopathic Pulmonary FibrosisMultiple Myeloma Refractory

Phase 1

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

CompletedNCT04540770

HuniLife Biotechnology, Inc.Idiopathic Pulmonary Fibrosis

Start: 2021-08-31End: 2024-01-19Updated: 2025-09-24

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

RecruitingNCT07210047

HuniLife Biotechnology, Inc.Multiple Myeloma Refractory

Start: 2025-08-18End: 2028-01-31Target: 21Updated: 2026-09-18

Related Papers

Abstract LB233: Targeting ENO1 to tilt the immunometabolic balance in the tumor microenvironment of KRAS-mutated colorectal cancer to improve therapeutic efficacy

Cancer Research2025-04-25

Abstract LB067: Extracellular enolase-1 drives cancer-associated fibroblast differentiation in the tumor microenvironment to enhance tumor growth of multiple myeloma: Development of the therapeutic antibody, HuL001

Cancer Research2025-04-25